(redirected from common variable immunodeficiency)
Also found in: Dictionary, Medical, Acronyms, Encyclopedia, Wikipedia.
  • noun

Antonyms for immunodeficiency

immunological disorder in which some part of the body's immune system is inadequate and resistance to infectious diseases is reduced

References in periodicals archive ?
Clinical and immunological spectrum of common variable immunodeficiency (CVID).
Cytokine production by activated T cells in common variable immunodeficiency.
Dominant-negative effect of the heterozygous C104R TACT mutation in common variable immunodeficiency (CVID).
High serum levels of BAFF, APRIL, and TACT in common variable immunodeficiency.
T-cell abnormalities in common variable immunodeficiency.
Pulmonary mucosa-associated lymphoid tissue lymphoma in a patient with common variable immunodeficiency syndrome.
To the best of our knowledge, immune complexes have not been definitively reported in common variable immunodeficiency, although these patients are subject to diseases of an autoimmune nature in which such complexes might be expected.
2) Interestingly, lymphocytes from some patients with common variable immunodeficiency are deficient in gamma interferon production.
Common variable immunodeficiency (CVID) is primarily a disorder of B-cell differentiation; in some cases T-lymphocyte dysfunction may be seen as well.
Granulomatous disease in common variable immunodeficiency.
Common variable immunodeficiency (CVID) is a heterogeneous orphan condition characterized by hypogammaglobulinemia, recurrent sinopulmonary infections, and in some patients gastrointestinal manifestations such as chronic diarrhea and weight loss.
Individuals interested in Albuferon, BLyS or clinical trials for ulcerative colitis, common variable immunodeficiency or hepatitis C are encouraged to contact Human Genome Sciences at 301-610-5790, extension 3550, or via the Internet at http://www.
Common variable immunodeficiency (CVID) is a group of immunodeficiency syndromes in which B cell immunity is abnormal.
Nasdaq: HGSI) today announced that it will initiate human clinical trials of B-lymphocyte stimulator, or BLyS, in patients with Common Variable Immunodeficiency, a serious defect of the immune system.
Common Variable Immunodeficiency, or CVID, is one of a group of primary immunodeficiency disorders that are characterized by increased susceptibility to infection.